Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. Yoo T, Joo SK, Kim HJ, Kim HY, et al. J Hepatol 2021;75:514-523.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yoo T, Joo SK, Kim HJ, Kim HY, et al. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. J Hepatol 2021;75:514-523.
PMID: 33892010